by Ket Patel | Sep 16, 2012 | All Articles For Neurology, Multiple Sclerosis
The Food and Drug Administration has approved the latest oral therapy for relapsing multiple sclerosis, teriflunomide (Aubagio), but it will carry a strong warning that it increases the risk of fetal harm. The drug, made by the Genzyme division of Sanofi Aventis, is...
by Ket Patel | Sep 12, 2012 | All Articles For Neurology, Multiple Sclerosis
Glatiramer acetate and interferon beta-1a used in combination were no more effective for patients with relapsing-remitting multiple sclerosis than were either agent alone in a 3-year, randomized trial. On quality of life measures, monotherapy and combination therapy...
by Ket Patel | Sep 11, 2012 | All Articles For Neurology, Multiple Sclerosis
Bernd Krone, Institute of Virology, University Göttingen, Göttingen, Germany, and Laboratory Medicine Institute Kassel, Druseltalstrasse 61, 34131 Kassel, Germany, Email b.krone@staber-kollegen.de A recent epidemiologic study by Ajdacic-Gross et al. might give an...
by Ket Patel | Sep 11, 2012 | All Articles For Neurology, Multiple Sclerosis
Nina Grytten Torkildsen National Multiple Sclerosis Competence Centre, Dept. of Neurology, Haukeland University Hospital Norway Although everyone with relapsing remitting multiple sclerosis (RRMS) is advised to begin disease modifying therapy (DMT) in accordance with...
by Ket Patel | Sep 11, 2012 | All Articles For Psychiatry, Sleep Disorders
F. Angelico, M. Del Ben, M. Fabiani, Department of Internal Medicine and Medical Specialities, Sapienza University, Rome, Italy Several studies have provided evidence supporting an increase of oxidative stress in OSAS. Oxidative stress is a major component in...